Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Saglimbene, Valeria M ^a,b   Palmer, Suetonia C ^c   Ruospo, Marinella ^a   Natale, Patrizia ^a   Craig, Jonathan C ^b,d   Strippoli, Giovanni F M ^a,b,d,e,f  

^a Medical Scientific Office   (Sweden)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF BARI   (Italy)

^f Diaverum Academy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANEMIA; ARTERIOVENOUS GRAFT THROMBOSIS; BLOOD TRANSFUSION; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONSTIPATION; DIARRHEA; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; HEADACHE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFLUENZA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ADULT; ADVERSE EFFECTS; AGED; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION; ERYTHROCYTE TRANSFUSION; META ANALYSIS; MIDDLE AGED; PUBLISHING; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANEMIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DARBEPOETIN ALFA; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HUMANS; HYPERTENSION; MIDDLE AGED; POLYETHYLENE GLYCOLS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; THROMBOSIS;

EID: 85026795358     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009904.pub2     Document Type: Review

References (150)

1. Al-Ali FS, El-Sayed AM, Fawzy AA, Hamdy AF, Abdulla AE. Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International 2015;19(1):33-43. [MEDLINE: 24894344]6374950
2. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]6374952
3. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi342. [CENTRAL: CN-00757502]6374953
4. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6374954
5. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA-PO212]. Journal of the American Society of Nephrology 2006;17(Abstracts):620A. [CENTRAL: CN-00644218]6374955
6. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases 2007;50(6):989-1000. [MEDLINE: 18037099]6374956
7. Provenzano R, Macdougall IC, Law A, Ouyang Y, Bexon M. Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU-PO796]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00747311]6374957
8. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6374959
9. Kessler M, Martinez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International 2010;14(2):233-9. [MEDLINE: 19888948]6374960
10. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA-PO208]. Journal of the American Society of Nephrology 2006;17(Abstracts):619A. 6374961
11. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(2):337-47. [MEDLINE: 18287255]6374962
12. Provenzano R, Macdougall IC, Law A, Ouyang Y, Bexon M. Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU-PO796]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00747311]6374963
13. Walker R, Macdougall IC, Levin A, Kessler M, Noble S, Burgos-Calderon R, et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52-week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi412. [CENTRAL: CN-00644215]6374964
14. Dougherty FC, Reigner B, Beyer U. Dose-dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple-dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:325. [CENTRAL: CN-00509162]6374966
15. Provenzano R, Dougherty FC. Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases 2006;47(4):A50. [CENTRAL: CN-00747315]6374967
16. de Francisco AL, Sulowicz W, Dougherty FC. Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple-dose study [abstract no: SA-FC124]. Journal of the American Society of Nephrology 2003;14(Nov):27A-8A. [CENTRAL: CN-00550366]6374968
17. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776-7]. International Journal of Clinical Practice 2006;60(12):1687-96. [MEDLINE: 17109676]6374969
18. Besarab A, Beyer U, Dougherty FC. Long-term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W-PO40127]. Nephrology 2005;10(Suppl 1):A312-3. [CENTRAL: CN-00747326]6374971
19. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clinical Therapeutics 2007;29(4):626-39. [MEDLINE: 17617286]6374972
20. Dougherty FC, Beyer U. No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W-PO40131]. Nephrology 2005;10(Suppl 1):A313-4. [CENTRAL: CN-00602138]6374973
21. Dougherty FC, Beyer U. Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W-PO40130]. Nephrology 2005;10(Suppl 1):A313. [CENTRAL: CN-00602137]6374974
22. Dougherty FC, Loghman-Adham M, Schultze N, Beyer U. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v269. [CENTRAL: CN-00602143]6374975
23. Dutka P, Tilocca P, BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal 2006;33(2):138. [CENTRAL: CN-00602144]6374976
24. Salifu M, Villa G, Dougherty FC. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre-existing conditions [abstract no: 138]. American Journal of Kidney Diseases 2006;47(4):A53. [CENTRAL: CN-00602141]6374977
25. Dougherty FC, Beyer U. No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W-PO40131]. Nephrology 2005;10(Suppl 1):A313-4. [CENTRAL: CN-00602138]6374979
26. Dougherty FC, Beyer U. Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W-PO40130]. Nephrology 2005;10(Suppl 1):A313. [CENTRAL: CN-00602137]6374980
27. Dougherty FC, Loghman-Adham M, Schultze N, Beyer U. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v269. [CENTRAL: CN-00602143]6374981
28. Dutka P, Tilocca P, BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal 2006;33(2):138. [CENTRAL: CN-00602144]6374982
29. Locatelli F, Villa G, Arias M, Marchesi D, Dougherty FC, Beyer U, et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU-PO051]. Journal of the American Society of Nephrology 2004;15(Oct):543A. [CENTRAL: CN-00626008]6374983
30. Locatelli F, Villa G, Beyer U, Dougherty FC. Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v261. [CENTRAL: CN-00602142]6374984
31. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research & Opinion 2007;23(5):969-79. [MEDLINE: 17519064]6374985
32. Salifu M, Villa G, Dougherty FC. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre-existing conditions [abstract no: 138]. American Journal of Kidney Diseases 2006;47(4):A53. [CENTRAL: CN-00602141]6374986
33. Chen N, Qian JQ, Mei CL, Zhang AH, Xing CY, Wang L, et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial. Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine] 2012;51(7):502-7. [MEDLINE: 22943819]6374988
34. Martinez-Castelao A. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus 2010;3(Suppl 3):iii298. [EMBASE: 70484207]6374990
35. Roger S. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology 2010;15(Suppl 4):79. [EMBASE: 70467206]6374991
36. Roger SD. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus 2010;3(Suppl 3):iii219-iii220. [EMBASE: 70484001]6374993
37. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation 2011;26(12):3980-6. [MEDLINE: 21505096]6374992
38. Forni V, Bianchi G, Ogna A, Salvade I, Vuistiner P, Burnier M, et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology 2013;14(1):157. [MEDLINE: 23870287]6374995
39. Furukawa T, Okada K, Abe M, Tei R, Oikawa O, Maruyama N, et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre-dialysis stage. International Journal of Molecular Sciences 2015;16(12):30181-9. [MEDLINE: 26694377]6374997
40. Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis & Dialysis 2014;18(5):421-6. [MEDLINE: 24456328]6374999
41. Kuji T, Fujikawa T, Kakimoto-Shino M, Shibata K, Toya Y, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation 2013;28(Suppl 1):i244-5. [EMBASE: 71075732]6375000
42. Kinugasa E, Yumita S, Sato T, Kurosawa A, Kitaoka T, Sugimoto H, et al. A dose-finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis - A randomized double-blind comparative study. Japanese Pharmacology & Therapeutics 2011;39(Suppl 1):S9-S19. [EMBASE: 2011317486]6375002
43. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU-PO795]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00794522]6375004
44. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]6375005
45. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi342. [CENTRAL: CN-00757502]6375006
46. Fishbane S, Bernardo M, Locatelli F, delAguila M, Edwardes M, Bexon M. Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU-PO779]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):756A. [CENTRAL: CN-00757405]6375007
47. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6375008
48. Fishbane S, Levin NW, Mann JF, Lewis JL, Bernardo M, Lunde NM, et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1-3 times per week in patients with CKD on dialysis [abstract no: SA-PO205]. Journal of the American Society of Nephrology 2006;17(Abstracts):618A. [CENTRAL: CN-00757097]6375009
49. Fishbane S, Liu S, Beswick R, Nissenson A. C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F-PO834]. Journal of the American Society of Nephrology 2007;18(Abstracts):285A. 6375010
50. Imbasciati E, Bernardo M, Caraman P, David-Neto E, Harris K, Law A, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients with varying C-reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi412. [CENTRAL: CN-00758076]6375011
51. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet 2007;370(9596):1415-21. [MEDLINE: 17950856]6375012
52. Levin NW, Fishbane S, Zeig S, Nassar G, Moran J, Villa G, et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv11. [CENTRAL: CN-00757059]6375013
53. Levin NW, Imbasciati E, Combe C, Rocco MV, Lok CE, Donnelly SM, et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA-PO206]. Journal of the American Society of Nephrology 2006;17(Abstracts):619A. [CENTRAL: CN-00755210]6375014
54. Mann J, Locatelli F, Sulowicz W, Nissenson A, Portoles J, Levin N, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi411. [CENTRAL: CN-00791257]6375015
55. Nissenson A, Kwok A, Beswick R, Fishbane S. C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases 2007;49(4):A39. 6375016
56. Nissenson A, Nassar G, Edwardes M, Beswick R, Berns J. C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F-PO855]. Journal of the American Society of Nephrology 2007;18(Abstracts):290A-1A. 6375017
57. Ryckelynck JP, Valdes Canedo F, Riella M, Lempert K, Donnelly S, Adrogue H, et al. Once-monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi411. [CENTRAL: CN-00644372]6375018
58. Meier P. Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end-stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly 2008;138(Suppl 167):22S. 6375021
59. Meier P, Meier R. Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end-stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. 6375020
60. NCT00442702. A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). 6375023
61. Locatelli F, Choukroun G, Truman M, Wiggenhauser A, Fliser D. Once-monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis-dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy 2016;33(4):610-25. [MEDLINE: 26965694]6375025
62. NCT00717821. A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). 6375026
63. Oh J, Joo K, Chin H, Chae DW, Kim SG, Chung WK, et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus 2010;3(Suppl 3):iii502-3. [EMBASE: 70484793]6375028
64. Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. Journal of Korean Medical Science 2014;29(1):76-83. [MEDLINE: 24431909]6375029
65. Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School] 2015;82(1):21-6. [MEDLINE: 25797871]6375031
66. Besarab A, Canaud B, de Francisco ALM, Kerr P, Locatelli F, Lok CE, et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology 2006;17(Abstracts):896A. [CENTRAL: CN-00740564]6375033
67. Carrera F. C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. 6375035
68. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation 2010;25(12):4009-17. [MEDLINE: 20522670]6375034
69. Locatelli F, PATRONUS Study Group. Once-monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA-PO2412]. Journal of the American Society of Nephrology 2009;20:663A. [CENTRAL: CN-00747328]6375036
70. Mann JF, PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once-monthly C.E.R.A. or once-monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology 2009;20:921A. [CENTRAL: CN-00747329]6375037
71. de Francisco AL, PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once-monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA-PO2411]. Journal of the American Society of Nephrology 2009;20:663A. [CENTRAL: CN-00747327]6375038
72. Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser IA. The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemporary Clinical Trials 2011;32(6):786-92. [MEDLINE: 21762788]6375040
73. Fliser D, Dellanna F, Koch M, Wiggenhauser A, PRIMAVERA Study Group. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial. Nephrology Dialysis Transplantation 2017;32(2):279-87. [MEDLINE: 28186540]6375041
74. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU-PO795]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00794522]6375043
75. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]6375044
76. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi342. [CENTRAL: CN-00757502]6375045
77. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6375046
78. Fishbane S, Liu S, Beswick R, Nissenson A. C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F-PO834]. Journal of the American Society of Nephrology 2007;18(Abstracts):285A. 6375047
79. Imbasciati E, Bernardo M, Caraman P, David-Neto E, Harris K, Law A, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients with varying C-reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi412. [CENTRAL: CN-00758076]6375048
80. Locatelli F, Sulowicz W, Harris K, Selgas R, Kaufman J, Klinger M, et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1-3 times per week in patients with CKD on dialysis [abstract no: SA-PO207]. Journal of the American Society of Nephrology 2006;17(Abstracts):619A. [CENTRAL: CN-00626009]6375049
81. Nissenson A, Kwok A, Beswick R, Fishbane S. C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases 2007;49(4):A39. 6375050
82. Ryckelynck JP, Harris K, Selgas R, Stompor T, Ladanyi E, Opatrna S, et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA-PO210]. Journal of the American Society of Nephrology 2006;17(Abstracts):620A. [CENTRAL: CN-00644371]6375051
83. Ryckelynck JP, Valdes Canedo F, Riella M, Lempert K, Donnelly S, Adrogue H, et al. Once-monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi411. [CENTRAL: CN-00644372]6375052
84. Sulowicz W, Locatelli F, Balla J, Csiky B, Rikker C, Aldigier J, et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv156-7. [CENTRAL: CN-00601914]6375053
85. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN 2007;2(4):637-46. [MEDLINE: 17699476]6375054
86. Besarab A, Provenzano R, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, et al. Dose-dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi-dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA-PO930]. Journal of the American Society of Nephrology 2005;16:760A. [CENTRAL: CN-00747325]6375056
87. Provenzano R, Besarab A, Macdougall IC, Dougherty FC, Beyer U. CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU-PO056]. Journal of the American Society of Nephrology 2004;15(Oct):544A. [CENTRAL: CN-00747313]6375057
88. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA-PO929]. Journal of the American Society of Nephrology 2005;16:760A. [CENTRAL: CN-00747324]6375058
89. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology 2007;67(5):306-17. [MEDLINE: 17542340]6375059
90. Provenzano R, Dougherty FC. Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases 2006;47(4):A50. [CENTRAL: CN-00747315]6375060
91. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU-PO795]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00794522]6375062
92. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6375063
93. Spinowitz B, Coyne DW, Fraticelli M, Azer M, Dalal S, Villa G, et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre-filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology 2006;17(Abstracts):895A. [CENTRAL: CN-00653773]6375064
94. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology 2008;28(2):280-9. [MEDLINE: 18004064]6375065
95. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU-PO795]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):760A. [CENTRAL: CN-00794522]6375067
96. Canaud B, Braun J, Locatelli F, Villa G, Van Vlem B, Sanz Guajardo D, et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv157. [CENTRAL: CN-00690645]6375068
97. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation 2008;23(11):3654-61. [MEDLINE: 18586762]6375069
98. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]6375070
99. Campistol JM, Carreno A, Morales JM, Pallardo L, Franco A, Navarro D, et al. Once-monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation 2013;95(2):e6-e10. [MEDLINE: 23325012]6375072
100. Carreno A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus 2011;4(Suppl 2):4.s2.32. 6375073
101. Carreno A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation 2011;11:36. [EMBASE: 70405062]6375074
102. Toida T, Sato Y, Fujimoto S. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation 2014;29(Suppl 3):iii499-iii500. [EMBASE: 71492907]6375076
103. Toida T, Sato Y, Shibata N, Kitamura K, Fujimoto S. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification 2014;38(3-4):174-9. [MEDLINE: 25502179]6375077
104. Tsubakihara Y, Bessho M, Suzuki M, JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non-inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus 2011;4(Suppl 2):4.s2.32. 6375079
105. Macdougall IC, Reigner B, Dougherty FC. Consistent pharmacokinetic properties of CERA (Continuous Erythropoietin Receptor Activator) in healthy volunteers and in patients with CKD) [abstract no: 89]. American Journal of Kidney Diseases 2006;47(4):A41. [CENTRAL: CN-00583919]6375081
106. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN 2006;1(6):1211-5. [MEDLINE: 17699350]6375082
107. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Reigner B, et al. Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients (pts) following intravenous (IV) and subcutaneous (SC) administration [abstract no: SA-PO926]. Journal of the American Society of Nephrology 2005;16:759A. [CENTRAL: CN-00795029]6375083
108. Warwicker P. A randomised, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of anaemia in patients with chronic kidney disease. National Research Register, UK [www.nrr.nhs.uk/] 2004. [CENTRAL: CN-00487652]6375085
109. NCT00773513. A randomized, open label study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs. www.clinicaltrials.gov/ct2/show/NCT00773513 (first received 15 October 2008). 6375087
110. Ishikawa E. Methoxy polyethylene glycol-epoetin beta once a month versus darbepoetin alfa once a week for treatment of anemia in hemodialysis patients: a randomized, multicenter, open-label trial. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view cgi?recptno=R000009496 (first received 6 January 2012). 6375089
111. Mitsuiki K. Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view cgi?recptno=R000011078 (first received 4 December 2012). 6375091
112. Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. International Journal of Clinical Pharmacy 2014;36(6):1115-25. [MEDLINE: 25288147]
113. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [MEDLINE: 7786990]
114. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584-90. [MEDLINE: 9718377]
115. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Archives of Internal Medicine 2009;169(12):1104-12. [MEDLINE: 19546410]
116. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;355(20):2071-84. [MEDLINE: 17108342]
117. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001;84 Suppl 1:3-10. [MEDLINE: 11308268]
118. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. American Journal of Kidney Diseases 1996; Vol. 28, issue 1:53-61. [MEDLINE: 8712222]
119. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
120. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology & Therapeutics 1991;50(6):702-12. [MEDLINE: 1752115]
121. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57. [MEDLINE: 16345038]
122. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
123. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
124. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology 2002;13(2):504-10. [MEDLINE: 11805181]
125. Jarsch M, Kubbies M, Lanzendorfer M, Haselbeck A, Brandt M. CERA acts differently at the erythropoietin (EPO) receptor compared with epoetin beta: UT-7 and CD34+ cell stimulation assays [abstract no. SA-PO209]. 39th Annual Meeting and Scientific Exhibition of the American Society of Nephrology; Renal Week: 2006 Nov 14-19; San Diego (CA). 2006.
126. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 2002;39(2 Suppl 1):S1-266. [MEDLINE: 11904577]
127. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(4):1077-83. [MEDLINE: 18417744]
128. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International 2006; Vol. 69, issue 3:560-4. [MEDLINE: 16395253]
129. Lacson E Jr, Qang W, Hakin RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. American Journal of Kidney Diseases 2009; Vol. 53, issue 1:79-90. [MEDLINE: 18930570]
130. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600. [MEDLINE: 16974018]
131. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrology Dialysis Transplantation 2007;22 Suppl 4:iv2-iv9. [MEDLINE: 17526547]
132. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clinical Pharmacokinetics 2006;45(5):503-10. [MEDLINE: 16640455]
133. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD010590.pub2]
134. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369(9559):381-8. [MEDLINE: 17276778]
135. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Archives of Internal Medicine 2009;169(19):1756-61. [MEDLINE: 19858432]
136. Roberts TL, Foley RN, Weinhandl ED, Gilbertson DT, Collins AJ. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrology Dialysis Transplantation 2006;21(6):1652-62. [MEDLINE: 16449283]
137. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time.[Erratum in Kidney Int. 2005 Dec;68(6):2934]. Kidney International 2005;68(5):2323-30. [MEDLINE: 16221236]
138. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. British Journal of Clinical Pharmacology 1990;26(6):709-13. [MEDLINE: 2378790]
139. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
140. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
141. Sinclair AM. Erythropoiesis stimulating agents: approaches to modulate activity. Biologics 2013;7:161-74. [MEDLINE: 23847411]
142. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 2006;355(20):2085-98. [MEDLINE: 17108343]
143. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine 2010;363(12):1146-55. [MEDLINE: 20843249]
144. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. Journal of Clinical Epidemiology 2005;58(9):894-901. [MEDLINE: 16085192]
145. Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Winkelmayer WC, et al. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials [Electronic Resource] 2015;16:364. [MEDLINE: 26285819]
146. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009;361(21):2019-32. [MEDLINE: 19880844]
147. Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. American Journal of Kidney Diseases 2015;66(1):69-74. [MEDLINE: 25636816]
148. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2(8517):1175-8. [MEDLINE: 2877323]
149. Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, et al. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. American Journal of Kidney Diseases 2015;66(1):106-13. [MEDLINE: 25943715]
150. Palmer SC, Nand K, Dwi Nur Hidayati L, Munasinghe A, Nelson C, Khafaji MM, et al. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009904]